DAFTAR PUSTAKA

Ainuddin, JA. 2015. Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome. J Coll Physicians Surg Pak. 2015; 25(4):237-41.

Arain, F. 2015. Frequency and outcome of treatment in polycystic ovaries related infertility. Pak J Med Sci. 2015; 31(3):694-9.

Djuwantono, T, Tjahyadi, D, Ritonga M A. 2010. Isu Terkini Penanganan yang Tepat Dampak Metabolik Sindroma Polikistik Ovarium. Continuing Medical Education. Bandung: Fakultas Kedokteran Universitas Padjadjaran.

Dumitrescu, R. 2015. Metformin-clinical pharmacology in PCOS. J Med Life. 2015; 8(2):187-92.

Foretz M., Hebrard S., Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al.. 2010. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120:2355–2369.

Foretz M., Viollet B.. 2011. Regulation of hepatic metabolism by AMPK. J Hepatol. 2011; 54:827–829.

Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E.. 2012. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics, 22(11), 820–827.

Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., et al.. 2012. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011; 50:81–98.

Hashim, Abu. 2015. Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2015; 8(2):187-92.

Kim Y. D., Park K. G., Lee Y. S., Park Y. Y., Kim D. K., Nedumaran B., et al.. 2008. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008; 57:306–314.

Maharani, L dan Wratsangka, R. 2012. Sindrom Ovarium Polikistik: Permasalahan dan Penatalaksanaannya. J Kedokteran Trisakti. Vol 21 No 3: 98-103.

Minematsu T., Giacomini K. M.. 2011. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011 ; 10:531–539.

Muller J., Lips K. S., Metzner L., Neubert R. H., Koepsell H., Brandsch M.. 2005. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 ; 70:1851–1860.

Naderpoor, N. 2014. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2014; 42(3):315-20. 

Nies A. T., Hofmann U., Resch C., Schaeffeler E., Rius M., Schwab M. 2011. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One. 2011; 6 : 22163.

Rojas, J., Chávez-Castillo M., Torres W., Arraiz N., Cabrera M., et al.. 2014. Metformin in Cancer: Chemical Pathways for Tumoral Control Independent of Amp-Dependent Kinase. J Endocrinol Diabetes Obes 2(2): 1036.

Somogyi A., Stockley C., Keal J., Rolan P., Bochner F.. 1987. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987; 23:545–551.

Suherman, S. K.. 2009. Insulin dan Antidabetik Oral. Farmakologi dan Terapi Edisi 5. Jakarta : Balai Penerbit FKUI.

Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. 2008. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008; 9:415–422.

Tzvetkov M. V., Vormfelde S. V., Balen D., Meineke I., Schmidt T., Sehrt D., et al.. 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009; 86:299–306.

Zhou M., Xia L., Wang J.. 2007. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007; 35:1956–1962.